This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Radiation Therapy  • Ocular/ Adnexal Tumors  • Retinal/ Chorioretinal Disorders  • Alert me on articles by topic

COMS Report No. 25

Collaborative Ocular Melanoma Study Group^*

Arch Ophthalmol. 2005;123:601-604.

Objective  To report sites of second primary cancer and the time to first diagnosis during routine follow-up after treatment for choroidal melanoma.

Design  Prospective longitudinal follow-up of patients enrolled in 2 randomized trials conducted by the Collaborative Ocular Melanoma Study (COMS) Group.

Methods  Baseline and annual or semiannual systemic and laboratory evaluations were performed according to a standard protocol for 2320 patients enrolled in the COMS without evidence of melanoma metastasis or other primary cancer at baseline. Deaths were coded by a mortality coding committee.

Results  Subsequent to treatment for choroidal melanoma, a total of 222 patients were diagnosed with a second primary cancer other than basal or squamous cell skin cancer (5-year rate of 7.7% [95% confidence interval, 6.6%-9.0%]). The most common sites were prostate (23% of reported cases) and breast (17%); 12 of these 222 patients were diagnosed simultaneously with second primary cancers in 2 or more sites. Of these 222 patients, 113 died; 37 (33%) were coded as dead with melanoma metastasis, 33 (29%) as dead with a malignant tumor other than metastatic melanoma, and 13 (11%) as dead with a malignancy of uncertain origin. Radiotherapy did not significantly increase the development of second primary cancers. The rate of diagnosis of second primary cancer did not differ significantly by smoking status, although the rate in former smokers was increased vs that observed in either current smokers or those who never smoked.

Conclusion  Routine medical surveillance for development of second primary cancers among patients treated for choroidal melanoma is important, especially for those with a history of smoking, regardless of the size of choroidal melanoma at the time of treatment.

*Authors: This report was prepared on behalf of the Collaborative Ocular Melanoma Study (COMS) Group by Marie Diener-West, PhD; Sandra M. Reynolds, MA; Donna J. Agugliaro, RN, BSN; Robert Caldwell, PA; Kristi Cumming, RN, MSN; John D. Earle, MD; Barbara S. Hawkins, PhD; James A. Hayman, MD; Ishmael Jaiyesimi, MD; John M. Kirkwood, MD; Wui-Jin Koh, MD; Dennis M. Robertson, MD; John M. Shaw, MD; Bradley R. Straatsma, MD, JD; Jonni Thoma, RN, BSN.
Group Information: A complete list of the members of the COMS Group can be found at Arch Ophthalmol. 2001;119:961-965.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Uveal Melanoma: A Study on Incidence of Additional Cancers in the Swedish Population
Bergman et al.
IOVS 2006;47:72-77.
ABSTRACT | FULL TEXT